PMC:7381711 / 13352-14041 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T98","span":{"begin":62,"end":69},"obj":"Body_part"},{"id":"T99","span":{"begin":138,"end":145},"obj":"Body_part"},{"id":"T100","span":{"begin":156,"end":174},"obj":"Body_part"},{"id":"T101","span":{"begin":275,"end":290},"obj":"Body_part"},{"id":"T102","span":{"begin":598,"end":605},"obj":"Body_part"},{"id":"T103","span":{"begin":610,"end":617},"obj":"Body_part"}],"attributes":[{"id":"A98","pred":"fma_id","subj":"T98","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A99","pred":"fma_id","subj":"T99","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A100","pred":"fma_id","subj":"T100","obj":"http://purl.org/sig/ont/fma/fma63011"},{"id":"A101","pred":"fma_id","subj":"T101","obj":"http://purl.org/sig/ont/fma/fma63023"},{"id":"A102","pred":"fma_id","subj":"T102","obj":"http://purl.org/sig/ont/fma/fma82839"},{"id":"A103","pred":"fma_id","subj":"T103","obj":"http://purl.org/sig/ont/fma/fma82839"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}

{"project":"LitCovid-PubTator","denotations":[{"id":"471","span":{"begin":356,"end":361},"obj":"Species"},{"id":"472","span":{"begin":362,"end":375},"obj":"Species"},{"id":"473","span":{"begin":405,"end":422},"obj":"Species"},{"id":"474","span":{"begin":427,"end":438},"obj":"Species"},{"id":"475","span":{"begin":649,"end":662},"obj":"Species"},{"id":"476","span":{"begin":62,"end":69},"obj":"Chemical"},{"id":"477","span":{"begin":138,"end":145},"obj":"Chemical"},{"id":"478","span":{"begin":156,"end":174},"obj":"Chemical"},{"id":"479","span":{"begin":275,"end":290},"obj":"Chemical"},{"id":"480","span":{"begin":598,"end":605},"obj":"Chemical"},{"id":"481","span":{"begin":610,"end":617},"obj":"Chemical"},{"id":"482","span":{"begin":540,"end":548},"obj":"Disease"},{"id":"483","span":{"begin":640,"end":648},"obj":"Disease"}],"attributes":[{"id":"A471","pred":"tao:has_database_id","subj":"471","obj":"Tax:9606"},{"id":"A472","pred":"tao:has_database_id","subj":"472","obj":"Tax:11118"},{"id":"A473","pred":"tao:has_database_id","subj":"473","obj":"Tax:11103"},{"id":"A474","pred":"tao:has_database_id","subj":"474","obj":"Tax:39059"},{"id":"A475","pred":"tao:has_database_id","subj":"475","obj":"Tax:11118"},{"id":"A476","pred":"tao:has_database_id","subj":"476","obj":"MESH:D006493"},{"id":"A477","pred":"tao:has_database_id","subj":"477","obj":"MESH:D006493"},{"id":"A478","pred":"tao:has_database_id","subj":"478","obj":"MESH:D006025"},{"id":"A479","pred":"tao:has_database_id","subj":"479","obj":"MESH:D006497"},{"id":"A480","pred":"tao:has_database_id","subj":"480","obj":"MESH:D006493"},{"id":"A481","pred":"tao:has_database_id","subj":"481","obj":"MESH:D006493"},{"id":"A482","pred":"tao:has_database_id","subj":"482","obj":"MESH:C000657245"},{"id":"A483","pred":"tao:has_database_id","subj":"483","obj":"MESH:D015047"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T121","span":{"begin":405,"end":416},"obj":"Disease"},{"id":"T122","span":{"begin":405,"end":414},"obj":"Disease"},{"id":"T123","span":{"begin":540,"end":548},"obj":"Disease"}],"attributes":[{"id":"A121","pred":"mondo_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/MONDO_0005231"},{"id":"A122","pred":"mondo_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/MONDO_0002251"},{"id":"A123","pred":"mondo_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T68","span":{"begin":196,"end":199},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T69","span":{"begin":294,"end":295},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T70","span":{"begin":356,"end":361},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T71","span":{"begin":417,"end":422},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T72","span":{"begin":460,"end":461},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T145","span":{"begin":62,"end":69},"obj":"Chemical"},{"id":"T146","span":{"begin":92,"end":101},"obj":"Chemical"},{"id":"T147","span":{"begin":138,"end":145},"obj":"Chemical"},{"id":"T148","span":{"begin":156,"end":174},"obj":"Chemical"},{"id":"T149","span":{"begin":178,"end":187},"obj":"Chemical"},{"id":"T150","span":{"begin":275,"end":290},"obj":"Chemical"},{"id":"T151","span":{"begin":275,"end":282},"obj":"Chemical"},{"id":"T152","span":{"begin":283,"end":290},"obj":"Chemical"},{"id":"T153","span":{"begin":296,"end":304},"obj":"Chemical"},{"id":"T154","span":{"begin":573,"end":582},"obj":"Chemical"},{"id":"T155","span":{"begin":598,"end":605},"obj":"Chemical"},{"id":"T156","span":{"begin":610,"end":617},"obj":"Chemical"},{"id":"T157","span":{"begin":623,"end":628},"obj":"Chemical"}],"attributes":[{"id":"A145","pred":"chebi_id","subj":"T145","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A146","pred":"chebi_id","subj":"T146","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A147","pred":"chebi_id","subj":"T147","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A148","pred":"chebi_id","subj":"T148","obj":"http://purl.obolibrary.org/obo/CHEBI_18085"},{"id":"A149","pred":"chebi_id","subj":"T149","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A150","pred":"chebi_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/CHEBI_28815"},{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_24500"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_16189"},{"id":"A153","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_23357"},{"id":"A154","pred":"chebi_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A155","pred":"chebi_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A156","pred":"chebi_id","subj":"T156","obj":"http://purl.obolibrary.org/obo/CHEBI_28304"},{"id":"A157","pred":"chebi_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}

{"project":"LitCovid-sentences","denotations":[{"id":"T83","span":{"begin":0,"end":117},"obj":"Sentence"},{"id":"T84","span":{"begin":118,"end":255},"obj":"Sentence"},{"id":"T85","span":{"begin":256,"end":454},"obj":"Sentence"},{"id":"T86","span":{"begin":455,"end":689},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T13","span":{"begin":275,"end":290},"obj":"GlycoEpitope"}],"attributes":[{"id":"A13","pred":"glyco_epitope_db_id","subj":"T13","obj":"http://www.glycoepitope.jp/epitopes/EP0086"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T32","span":{"begin":405,"end":414},"obj":"Phenotype"}],"attributes":[{"id":"A32","pred":"hp_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/HP_0012115"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}

{"project":"2_test","denotations":[{"id":"32519894-16928753-2138183","span":{"begin":447,"end":448},"obj":"16928753"},{"id":"32519894-11518721-2138184","span":{"begin":450,"end":452},"obj":"11518721"}],"text":"Despite the promise of this concept, no clinical data linking heparin therapy to meaningful antiviral outcomes exist. However, the use of heparin and other glycosaminoglycans as antiviral therapy has significant potential for future clinical applications. The utilization of heparan sulfate as a cofactor for viral entry appears to be conserved across the human coronaviruses as discussed, as well as the hepatitis C virus and herpesvirus family (8, 37). With a more in-depth understanding, this therapeutic strategy could be optimized for COVID-19, which may inform broad antiviral treatment with heparin and heparin-like drugs for future zoonotic coronaviruses and other viral pathogens."}